The receipt of this permission paves way for the launch of Tremelimumab solution of 20 mg/ml in India. Tremelimumab, in combination with Durvalumab (Imfinzi), is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).

Tags: Previous Next
Generated by Feedzy